Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800311 | 0.68 | CHRNB2 (0.36) | LMNARECQLCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL11177986 | 0.68 | ALDH1A1 (0.44) | HSD17B10MAPTLMNAALDH1A1HPGD | |
| SCHEMBL11179513 | 0.67 | CAPN1 (0.53) | HSD17B10MAPTLMNAALDH1A1RECQL | |
| SCHEMBL23768192 | 0.66 | P2RX7 (0.49) | RECQLPOLB | |
| SCHEMBL3558573 | 0.66 | USP2 (0.52) | MAPTLMNARECQLCHRNB2CHRNB4 | |
| SCHEMBL19531864 | 0.66 | HDAC4 (0.65) | LMNAALDH1A1CHRNA7KDM1AHPGD | |
| SCHEMBL2535599 | 0.65 | — | — | |
| SCHEMBL21016700 | 0.64 | CHRNB2 (0.40) | LMNAALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12448293 | 0.64 | CHRNB2 (0.40) | LMNAALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2535597 | 0.64 | CHRNB2 (0.48) | ALDH1A1RECQLCHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192497-A1 | ANTIBODY-RECRUITING MOLECULES FOR THE TREATMENT OF CANCER | KLEO PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192497-A1 | ANTIBODY-RECRUITING MOLECULES FOR THE TREATMENT OF CANCER | PLAUR, C3AR1, C5AR1 | HSD17B10 4352/4885MAPT 3655/4885LMNA 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.